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ABSTRACT 
 
Background: Tuberculosis (TB) is a global public health concern. The new challenge in TB con-
trol is the development of TB multi drug resistance (MDR-TB). Indonesia ranks 8th highest in the 
incidence of MDR-TB with 8,900 MDR-TB cases in 2004. A case was defined as MDR-TB if the 
Mycobacterium tuberculosis was resistant to rifampicin dan isoniazid. This study aimed to 
determine the factors affecting the success of multi drug resistance (MDR-TB) tuberculosis 
treatment. 
Subjects and Method: This was an analytic observational study using case control design. The 
study was conducted at Dr. Moewardi Hospital, Surakarta, Central Java, Indonesia, in October 
2014. The case population were MDR-TB patients visiting Dr. Moewardi Hospital for TB treatment 
from 2011 to October 2014. A sample of 84 TB cases consisting of 26 patients who dropped out, 
defaulted, or died, and 58 patients who successfully completed TB treatment, were selected for this 
study. The independent variables were sex, age, marital status, nutrional status, education, 
employment status, drug side effect, family support, and distance to health facility. The dependent 
variable was success of treatment. The data were collected by direct interview, questionnaire, and 
medical record. Logistic regression was employed for data analysis. 
Results: Age (OR= 0.93; 95% CI= 0.88 to 0.97; p=0.004) and drug side effect (OR= 6.84; 95% 
CI= 2.50 to 18.74; p<0.001) affected the success of TB treatment and statistically significant. Sex 
(OR= 0.66; 95% CI= 0.17 to 2.58; p=0.556), education (OR=0.90; 95% CI= 0.52 to 1.58; p=0.724), 
employment status (OR= 0.87; 95% CI= 0.59 to 1.28; p=0.485) affected the success of TB 
treatment but statistically not significant. 
Conclusion: Success of TB treatment is affected by age and drug side effect.  
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BACKGROUND 
Tuberculosis (TB) disease is still a global 
health problem because it is the second 
deadly infectious disease after HIV / AIDS 
infection (WHO, 2015), even though 
control efforts with the Direct Observed 
Treatment Shortcourse (DOTS) strategy 
have been implemented in several countries 
since 1995. In 2015, the context of the 
Millennium Development Goals (MDGs) 
has shifted to a new era of Sustainable De-
velopment Goals (SDGs) which are applied 
to reduce morbidity and mortality due to 
TB disease (WHO, 2015). The World Bank 
stated that the DOTS strategy as a health 
intervention is cost effective, given that TB 
treatment takes 6 to 8 months of treatment, 
which requires a high cost. Tuberculosis 
can attack all ages, both adults and 
children. About 75% of those infected with 
TB are of productive age (15 to 50 years) 
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and 6% of children (Department of health, 
2014).  
It is estimated that there are 9.6 milli-
on people worldwide in 2014 infected with 
TB, 5.4 million men, 3.2 million women 
and 1 million children. Globally, 12% of 9.6 
million TB sufferers also suffer from HIV 
AIDS (WHO, 2015). Of the 9.6 million new 
TB cases in 2014, 58% were in Southeast 
Asia and the Western Pacific region. India, 
Indonesia and China have the largest 
number of TB cases, namely 23%, 10% and 
10% of the global total (WHO, 2015). 
Indonesia is a country with a high TB 
prevalence. According to the WHO report 
in 2015, Indonesia ranked second in the 
world with a total of 429 thousand TB 
patients (WHO, 2015). The prevalence of 
Indonesian population diagnosed with 
pulmonary TB by health personnel in 2013 
was 0.4 percent, not different from 2007. 
Five provinces with the highest pulmonary 
TB were West Java (0.7%), Papua (0.6%), 
DKI Jakarta (0.6%), Gorontalo (0.5%), 
Banten (0.4%) and West Papua (0.4%) 
(Ministry of Health RI, 2013). 
A new challenge in the treatment of 
TB in the world and Indonesia is the 
beginning of an increase in cases of Multi 
Drug Resistance TB (MDR-TB) which 
reaches 3.5% (WHO, 2015) and makes the 
problem of TB disease need special 
attention. About 480,000 cases of MDR TB 
(MDR-TB) are estimated to occur in 2014, 
only about a quarter of them were detected 
and reported. Globally, an estimated 3.3% 
of new TB cases and 20% of TB cases recur 
to MDR-TB. Globally, only 50% of MDR TB 
patients are successfully treated. In 2014, 
an estimated 190,000 people with MDR-TB 
died (WHO, 2015). 
The estimated prevalence of MDR TB 
in Indonesia in 2004 was 8,900 cases. Two 
percent of MDR TB cases are estimated to 
come from new TB cases and 14.7% of TB 
cases who receive repeat treatment. Based 
on the 2010 MDR TB Global Report, 
Indonesia is a country with MDR TB 
burden no. 8 in the world with an estimated 
new cases of MDR TB of 8900 people per 
year.  
Indonesia received an approval from 
the Green Light Committee in 2007 to treat 
100 patients with MDR TB. Since August 
2009, Indonesia began treatment of MDR 
TB patients in 2 locations, namely the 
Persahabatan Hospital, Jakarta and Dr. 
Soetomo, Surabaya (Burhan, 2010). In 
2010, the development has begun in several 
other regions, namely Malang and Sura-
karta (Ministry of Health RI, 2011.) 
MDR TB is a case of tuberculosis with 
resistance to at least 2 types of the most 
potent anti-tuberculosis drugs, namely 
Rifampicin and Isoniasid (INH) together or 
accompanied by other first-line OAT 
resistance such as Pyrazinamide, Etham-
butol and Streptomycin (Ministry of Health 
RI, 2014). Many factors have led to the 
increasing number of MDR-TB cases. The 
purpose of this study is to analyze the 
factors that influence the successful 
treatment of MDR TB patients in the Ex-
Surakarta Residency. 
 
SUBJECTS AND METHOD 
1. Study Design 
This was an analytic observational with a 
case control design. This study aimed to 
determine the factors that influence the 
success of MDR TB patient treatment.  
2. Population and Subjects 
The case population was MDR TB patients 
who went to Dr. Moewardi, Surakarta in 
2011 (early MDR TB program at Dr. 
Moewardi Hospital) until October 2014 
living in the former Surakarta Residency.  
Subjects of the case group were 
patients with MDR TB aged ≥14 years who 
dropped out, failed treatment, or died 
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amounting to 26 people. The subjects of the 
control group were TB patients aged ≥14 
years who had successfully completed 
treatment for about 58 people. 
The exclusion criteria of this study 
subject were patients who refused to parti-
cipate in the study, patients residing out-
side the former Surakarta Residency, pati-
ents moved to a residence outside the 
former Surakarta Residency, patients were 
not tracked and the patients whose medical 
record was missing or incomplete. 
3. Study Variables 
The dependent variable was the success of 
the treatment. The independent variables 
were gender, age, education, distance of 
residence of MDR TB patients with health, 
work, marital status, family assistance, 
drug side effects, family support and nutri-
tional status. 
4. Operational Definitions 
The operational definition of treatment 
success was MDR TB patients who have 
completed treatment and are declared as 
cured or complete the treatment.  
Education level was defined as a 
programmed and structured education that 
takes place at the school that is taken by the 
study subjects. 
The distance of residence with health 
facilities was the distance traveled by MDR 
TB patients from home to health facilities.  
Treatment accompaniment was the 
presence or absence of the accompanying 
family when the patient visits health faci-
lities. Side effects of treatment were effects 
that cause other complaints after the pati-
ent takes the drug given. 
Family support was the assessment of 
study subjects on the attitudes and be-
havior of family members during the 
treatment process. 
Nutritional status was the size of the 
patient's Body Mass Index (BMI) measured 
by height and weight with the formula BB 
(kg) /height (meters). 
5. Study Instruments 
Data on the success of MDR TB treatment, 
drug side effects, and nutritional status 
were measured using secondary data (re-
view of medical record documents). Other 
data were obtained using questionnaires 
and interviews. 
6. Data Analysis 
Univariate, bivariate data analysis were 
conducted with logistic regression test and 
knowing the risk ratio (odds ratio) and the 
multivariate was done using logistic 
regression test. 
 
RESULTS  
1. Characteristic of the subjects 
The frequency distribution of the case and 
control group study subjects is presented in 
Table 1. The study subjects who were male 
in the case group amounting to 15 people 
(57.7%) experienced treatment failure /died 
/dropped out. Subjects in the control group 
or successful in treatment were mostly 
female, amounting to 30 people (51.7%).  
Most of the study subjects in the case 
group were junior high school and senior 
high school graduates and there were eight 
for each (30.8%). Most of the study subjects 
in the control group were senior high 
school graduates of 26 people (44.8%). A 
total of 10 people (38.5%) in the case group 
worked as laborers. A total of 26 people 
(44.8%) in the control group did not work. 
Most of the study subjects in the case 
group lived 10 km from the place or about 
14 people (53.8%). There were 23 people 
(39.7%) in the case group who live ≥10 km. 
Study subjects in the case group 
consist of mostly married people for about 
22 people (84.6%). Most of the study 
subjects in the married status control group 
were 51 people (87.9%). There were study 
subjects whose status was widow / widower 
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in the case group and the control group of 1 
person each. 
Study subjects in the case group 
received family assistance for about 25 
(96.2%). Most of the control groups receiv-
ed family assistance of 54 people (93.1%). 
Most of the study subjects experienced a 
moderate level of treatment side effects 
consisting of 12 people (46.2%) in the group 
of cases and there were about 30 people 
(51.7%) in the control group. 
Most of the study subjects were un-
derweight, consisting of 15 people (57.7%) 
in the case group and 31 people (53.4%) in 
the control group. 
Table  1. The Distribution of case and control group frequency  
Variable Categoriy 
The Success of a Treatment 
Total 
Failed/ Died/ DO Treated 
N % n % n % 
Gender Male 15 57.7 28 48.3 43 51.2 
 Female 11 42.3 30 51.7 41 48.8 
Educational 
background 
No formal 
education 3 11.5 3 5.2 6 7.1 
PS 8 30.8 18 31.0 26 31.0 
JHS 7 26.9 9 15.5 16 19.0 
SHS 8 30.8 26 44.8 34 40.5 
Bachelor degree 0 0.0 2 3.4 2 2.4 
Occupation Not working 6 23.1 23 39.7 29 34.5 
Farmer 1 3.8 5 8.6 6 7.1 
Labor 10 38.5 10 17.2 20 23.8 
Seller 2 7.7 7 12.1 9 10.7 
Employee 4 15.4 6 10.3 10 11.9 
Etc. 3 11.5 7 12.1 10 11.9 
Residence 
Distance 
<5 km 7 26.9 13 22.4 20 23.8 
5-10 km 5 19.2 16 27.6 21 25.0 
≥10 km 14 53.8 29 50.0 43 51.2 
Marital status Single 3 11.5 6 10.3 9 10.7 
Married 22 84.6 51 87.9 73 86.9 
Widow/widower 1 3.8 1 1.7 2 2.4 
Family 
assistance 
No assistance 1 3.8 4 6.9 5 6.0 
Assistance 25 96.2 54 93.1 79 94.0 
Side effects                     Light    3 11.5 24 41.4 27 32.1 
Medium 12 46.2 30 51.7 42 50.0 
Serious 11 42.3 4 6.9 15 17.9 
Nutritional 
status 
Thin 
11 42.3 27 46.6 38 45.2 
 Normal 15 57.7 31 53.4 46 54.8 
 
2. Univariate Analysis 
Table 2 shows the results of the univariate 
analysis. The results of univariate analysis 
showed that the SD value was smaller than 
the mean value on the variables of age and 
family support. These results indicate that 
age and family support data are represen-
tative. The youngest age of this study 
subject was 19 years old and the oldest was 
80 years old. 
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Table 2.  The result of univariate analysis 
Variable Mean SD Minimum Maximum 
Age 42.76 13.68 19 80 
Family support     
Emotional support 14.00 1.50 10 16 
Appreciation support 15.54 0.98 12 16 
Informational support 14.89 1.43 10 16 
Intrumental support 14.31 1.83 9 16 
 
3. Bivariate Analysis 
Bivariate analysis was used to analyze the 
effect of each factor namely gender, age, 
education, occupation, distance of residen-
ce, marital status, family assistance, side 
effects of medication, family support, and 
nutritional status on the success of MDR TB 
treatment. 
Table 3 shows that treatment side 
effects have an effect on increasing the 
success of MDR TB treatment and it was 
statistically significant (OR= 4.83; 95% CI= 
2.06 to 11.33; p <0.001). Age influences the 
decreases of the success of MDR TB treat-
ment and it was statistically significant 
(OR= 0.95; 95% CI= 0.92 to 0.99; p= 
0.014). Gender (OR= 1.46; 95% CI= 0.57 to 
3.71; p= 0.426), education (OR= 1.36; 95% 
CI= 0.87 to 2.12; p= 0.180), distance of 
residence (OR= 1.01; 95% CI= 0.57 to 1.77; 
p= 0.973), and information support (OR= 
0.93; 95% CI= 0.68 to 1.28; p= 0.666) 
affect the success of MDR TB but it was not 
statistically significant.  
Table 3. The result of bivariate analysis  
Variables OR 
95% CI  
p 
Lower level Upper level 
Gender 1.46 0.57 3.71 0.426 
Age 0.95 0.92 0.99 0.014 
Education 1.36 0.87 2.12 0.180 
The distance of residence 1.01 0.57 1.77 0.973 
Occupation 0.87 0.67 1.14 0.314 
Marital Status 0.93 0.25 3.48 0.911 
Family assistance 0.54 0.06 5.08 0.590 
Drug side effects 4.83 2.06 11.33 <0.001 
Family Support 0.98 0.88 1.09 0.724 
Emosional 0.93 0.68 1.28 0.666 
Appreciation 0.79 0.47 1.32 0.366 
Informational 1.04 0.74 1.45 0.835 
Instrumental 0.99 0.76 1.28 0.933 
Nutritional Status 0.84 0.33 2.14 0.718 
 
Patient’s occupation (OR= 0.87; 95% 
CI= 0.67 to 1.14; p= 0.314), patient's 
marital status (OR= 0.93; 95% CI = 0.25 to 
3.48; p = 0.911), family income (OR = 0.54; 
95% CI= 0.06 to 5.08; p= 0.590), emo-
tional support (OR= 0.93; 95% CI= 0.88 to 
1.09; p= 0.724), support for awards (OR= 
0.79; 95% CI= 0.47 to 1.32; p= 0.366) , 
instrumental support (OR= 0.99; 95% CI= 
0.76 to 1.28; p= 0.933), and nutritional sta-
tus (OR= 0.84; 95% CI= 0.33 to 2.14; p 
=0.718) has an effect on reducing MDR TB 
success but is not statistically significant. 
4. Multivariate Analysis 
Multivariate analysis was carried out using 
logistic regression test. The results of 
multivariate analysis are shown in Table 4.  
The result of logistic regression ana-
lysis showed that side effects of drug use 
influence the treatment success in MDR TB 
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patients (OR= 6.84; 95% CI= 2.50 to 18.74; 
p< 0.001) and was statistically significant. 
The age of patients influences the process of 
reducing treatment success in MDR TB 
patients and it was statistically significant 
(OR= 0.93; 95% CI= 0.88 to 0.97; p= 
0.004). 
Gender (OR= 0.66; 95% CI= 0.17 to 
2.58; p= 0.556), education (OR= 0.90; 95% 
CI= 0.52 to 1.58; p= 0.724), and occupation 
(OR= 0.87; 95% CI= 0.59 to 1.28; p= 
0.485) have an effect on reducing treatment 
success in MDR TB patients but was not 
statistically significant. 
Table 4. The results of multivariate analysis of the effect of gender, age, 
education, occupation, and drug side effects on treatment success in MDR TB 
patients 
Variable OR 
CI 95% 
p 
Lower Level Upper Level 
Gender 0.66  0.17 2.58 0.556 
Age 0.93  0.88 0.97 0.004 
Education 0.90  0.52 1.58 0.724 
Occupation 0.87  0.59 1.28 0.485 
Drug side effects 6.84  2.50 18.74 <0.001 
 
DISCUSSIONS 
MDR TB is a case of Tuberculosis with 
resistance to at least 2 types of the most 
potent anti-tuberculosis drugs, namely 
Rifampicin and Isoniazid (INH) together or 
accompanied by other first-line OAT 
resistance such as Pyrazinamide, Etham-
butol and Streptomycin (Ministry health 
RI, 2014). The success of treatment for 
drug-resistant TB patients is divided into 
two, namely patients who successfully 
complete therapy, namely those whose 
treatment is complete or cured and do not 
succeed in completing therapy in accor-
dance with the 2014 MDR Tuberculosis 
Control Integrated Management Technical 
Guidelines (Ministry of Health, 2014).  
Estimated criteria for MDR-TB 
sufferers in Indonesia according to the 
Directorate General of Disease Control and 
Environmental Health (2014) and the 
Ministry of Health of RI (2014) include: 
1. TB patients who got failed treatment in 
2nd category.  
2. 2nd category treatment of TB patients 
which was not converted after 3 months 
of treatment.  
3. TB patients with 2nd category of 
treatment were not converted after 3 
months of treatment.  
4. TB patients who got failed treatment in 
1st category.  
5. TB patients with 1st category of 
treatment which was not converted. 
6. TB patients relapse after OAT therapy in 
1st and 2nd category.  
7. TB patients failed to get the treatment/ 
default.  
8. It was suspected that TB has a contact 
history of MDR-TB patients 
9. HIV-TB coinfected patients did not 
respond clinically or bacteriologically to 
OAT administration (if the initial 
diagnosis did not use the Molecular 
Rapid Test (MRT)). 
Drug-resistant tuberculosis patients 
were the patients who were infected by M. 
tuberculosis bacteria (through a Molecular 
Rapid Test (MRT) and resistant TB germs 
that were found (rifampicin) and cannot be 
treated with conventional OAT, including 
resistant poly, which was resistant to more 
than one type of first-line OAT beside 
Isoniazid (H) and Rifampicin (R) simultan-
eously, multi drug resistant (MDR) which 
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mean resistant to Rifampicin (R) and 
Isoniazid (H) simultaneously, monoristen, 
which mean resistance to one of the first-
line OAT, pre-Extensive Drug Resistant 
(XDR) including MDR-TB which was also 
resistant to one of the Fluoroquinolone 
OAT groups and at least one of the two 
types of OAT line injections (Kanamisin, 
Kapreomisin, and Amikasin). XDR and RR 
TB were resistant to Rifampicin with or 
without other OAT resistance which was 
detected by using the genotype method 
(rapid test) or phenotypic method (con-
ventional). 
A successful treatment was patients 
who were cured or patients with complete 
treatment. Patients with cured MDR-TB 
were patients who complete the therapy 
according to MDR-TB treatment guidelines 
without evidence of failure and culture 
results during the advanced stage which 
showed negative results at least 3 times in a 
row with a minimum intervals between the 
cultures of 30 days. Patients who have 
successfully completed MDR-TB treat-
ments (complete treatment) were patients 
who have completed the treatments acc-
ording to MDR-TB treatment guidelines 
but did not fulfill the cured or failed 
definition. 
Patients with MDR-TB who did not 
recover or complete the treatment were 
divided into two groups, namely the group 
of patients who died, which in this case was 
died of any cause during MDR-TB treat-
ment and the group of patients who failed, 
where MDR-TB treatment was stopped or 
needed changes in MDR-TB treatment 
guidelines permanently for two or more 
MDR-OAT caused by no conversion until 
the end of the 8th month of the intensive 
phase or conversion at an advanced stage. 
The sputum culture became positive on two 
consecutive examinations after previous 
conversion was achieved, or there was an 
evidence of additional resistance to fluoro-
quinolone class of MDR TB drugs or 
second-line injection drugs, or because of 
severe side effects which could stopped the 
therapy permanently. Lost to follow-up was 
a patient who was disconnected from treat-
ment for two consecutive months or more. 
Side effects of MDR-TB therapy were 
the side effects which obtained after taking 
anti MDR-TB drugs and there were no 
symptoms at previous therapy. Data was 
obtained from the medical records of drug 
resistant TB patients. Side effects of therapy 
variable were included in the type of 
ordinal scale. The assessment of side effects 
of MDR-TB therapy was divided into three 
types according to the Common Termin-
ology Criteria for Adverse Events (CTCAE) 
version 4.0 in 2009, namely mild/minor, 
moderate, and severe. 
Mild/minor side effects were defined 
as patients who did not feel the symptoms 
or symptoms that arised did not interfere 
the daily activities and did not require 
special therapy. 
Moderate side effects were defined as 
symptoms that interfere with the patient's 
daily activities, and it required medical the-
rapy, however, it did not require hospital 
treatment. 
Severe life-threatening side effects 
that cause death were defined as symptoms 
that unable the patient to carry out daily 
activities, it required hospital treatment, 
termination or replacement of MDR-TB 
therapy regimen, it also required invasive 
treatment, and it could lead to mortality. 
Family support was the assistances 
that can be given to other families in the  
form of goods, services, information, and 
advice, which made the family members felt 
comfortable, appreciated, and calm (Taylor, 
2006). Family support was highly needed 
in determining treatment adherence, if fa-
mily support was given to pulmonary TB 
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sufferers, especially MDR-TB, which took 
longer time (18 months to 2 years), it would 
motivate the patient to comply with the 
treatment and take the medication given by 
the health personnels. A number of other 
people who have the potential to provide 
such support were referred to significant 
others. 
According to Friedman (1998) and 
Bomar (2004), family support was divided 
into: 
1. Emotional support 
Communicate the love, care, and trust in 
family members. The family was considered 
as a safe and peaceful place for rest and 
recovery, and could help in mastering the 
emotions. This type of support was applied 
by involving expressions of empathy, caring 
for someone in order to provide a feeling of 
comfort, and making the individuals to feel 
better. Individuals regained self-confiden-
ce, feel owned and feel loved when they 
experienced stress. In this case, people who 
felt that they got this type of social support 
would feel relieved because they were 
noticed, got advice or a pleasant impression 
on themselves. 
2. Instrumental support 
Helping people directly include giving 
money and house work. This instrumental 
support referred to the provision of goods 
or services that can be used to solve 
practical problems. Taylor (2006) stated 
that the provision of instrumental support 
include the provision of financial support 
and the provision of other goods and 
services. This type of support was relevant 
for low economic circles. Family was a 
source of practical and concrete helps, 
including the health of TB patients which in 
this case were the adherence of TB patients 
in treatment, rest, and TB patients did not 
feel tired. 
3. Information support 
The aspects of this support were to give 
advice, suggestions, instructions, and infor-
mation. The functions of a family were as a 
collector and disseminator of information 
about the world. The family also explained 
about giving advice, suggestions, and 
information that can be used to reveal a 
problem. The benefit of family support was 
that it can suppress the emergence of a 
stressor because the information provided 
can contribute to specific suggestions to 
individuals. For example, by providing 
advices regarding the importance of the 
treatment and the consequences of not 
adhering to the medication. 
d. Appreciation support 
This type of support occurred through 
expressing positive appreciation for the 
individual, good encouragement or agree-
ment with the ideas or feelings of other 
individuals. In this case, the family acted as 
a guidance for feedback, guiding and sol-
ving the problems, and as a source and 
validator of family identities. They also 
helped people to learn about themselves 
and being someone in the same situation or 
similar experiences, similar in various 
important ways or made them feel  su-
pported by various ideas and feelings. The 
assessment of nutritional status in this 
study used the Body Mass Index (BMI) 
classification in Indonesia. 
Table 5. BMI Classification in 
Indonesia  
Category BMI 
Skinny  < 17 
Normal    17-25 
Fat 25.1-27 
Obesity ≥ 27 
Source : Health Department of  Republic of   
                Indonesia, 2010
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1. The Relationship between Age and 
Successful Treatment of MDR-TB 
Patients 
Descriptively, it can be seen that patients 
who have a risk of failure/mortality with an 
average age group of 48.42 ± 14.88 and 
those who recovered with an average age of 
40.22 ± 12.41. From the result of this study, 
it was known that the variable that 
influence the success of MDR-TB treatment 
was age variable with the score of OR= 
0.96; 95% CI= 0.92 to 0.99), and the score 
of p= 0.014, therefore, the older the MDR-
TB sufferers, the more likely to have a risk 
of failure/death/drop out. This showed that 
the younger the age of MDR-TB sufferers, 
the more successful the treatment. This was 
in accordance with a study of Anderson et 
al., (2012) which stated that age variable 
was related to the success of MDR-TB 
treatment (OR=1.00; p<0.001). Other 
study revealed that increased age has a ten-
dency to experience irregularity in taking 
medication.  
This was because older age needed 
additional support to access TB treatment 
(Wu et al., 2009). This condition certainly 
limited the ability of patients to came and 
took medication regularly at the Comm-
unity Health Center. A study done by Ibra-
him et al., (2014) found that there was no 
significant relationship of ≥35 years old age 
group and the success of treatment (OR= 
0.79; 95% CI= 0.34 to 1.44).  
2. The Relationship between Gender 
and Successful Treatment of MDR-
TB Patients. 
Statistically, there was no significant effect 
of gender on the success of MDR-TB 
treatment with a score of ≥35 years for the 
success of treatment (OR= 0.65; 95% CI= 
0.27 to 1.74; p= 0.426). This was in 
accordance with a study done by Anderson 
et al., (2012) which stated that there was no 
relationship between gender variable and 
the success of treatment (OR= 1.46; 95% CI 
= 0.76 to 2.85; p= 0.256).  
Previous study which stated that 
women were more likely to find health care 
and tend to be more obedient to treatment 
with DOTS compared to men (Wu et al., 
2009). Different opinions were obtained 
from study in Africa, Bangladesh and Syria 
which stated that married women tended to 
ask permission from their husbands to 
come to health services for TB treatment 
(Ibrahim et al., 2014). 
3. The Relationship between Level of 
Education and Successful Treat-
ment of MDR-TB Patients. 
Educational level could increase the success 
of the treatment of MDR-TB patients by 
1.36 times (OR= 1.36; 95% CI= 0.87 to 2.12; 
p= 0.180) even though it was statistically 
insignificant. The result was not in 
accordance with the previous study done by 
Kondoy et al., (2014) which stated that 
there was a relationship between level of 
education with treatment compliance which 
increased the success of TB treatment. 
4. The Relationship between the 
Distance to Health Facility and 
Successful Treatment of MDR-TB 
Patients. 
The distance of MDR-TB patients' residen-
ces was not related to the success of patient 
treatment (OR=1.01; 95% CI=0.57 to 1.77; 
p= 0.973). The result was not in accordance 
with a previous study done by Takarinda et 
al., (2015) which stated that the time taken 
by a patient from a residence to a health 
facility was significantly associated with a 
delay in TB treatment that could lead to 
failure treatment (OR= 0.47; 95% CI= 0.24 
to 0.94; p= 0.032).  
5. The Relationship between Employ-
ment and Successful Treatment of 
MDR-TB Patients. 
Patients who have employment reduced the 
success of treatment in MDR-TB (OR= 
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0.87; 95% CI= 0.67 to 1.14; p= 0.314). This 
was in accordance with previous study 
which stated that patients’ employment 
status was not related to irregularity in 
taking medication (OR=1.60; 95% CI= 0.66 
to 3.70) (Ibrahim et al., 2014).  
Similar study which was done by 
Kuchukhidze et al., (2014) revealed that 
there was no relationship between employ-
ment and drop out cases in TB treatment. 
Other study also stated that there was no 
relationship between employment and tre-
atment adherence of TB patients (Kondoy 
et al., 2014). A study done by Aibana et al., 
(2017) stated that employment has a sig-
nificant relationship with the success of 
treatment for MDR-TB sufferers. 
6. The Relationship between Marital 
Status and Successful Treatment of 
MDR-TB Patients. 
In this study, there was no relationship 
between marital status and the success of  
treatment for MDR-TB sufferers (OR= 
0.93; 95% CI= 0.25 to 3.48; p= 0.911). this 
was in accordance with the results of 
previous study which stated that marital 
status was not related to DO cases of TB 
patients (Kuchukhidze G et al., 2014). 
7. The Relationship between Family 
Assistance and Successful Treat-
ment of MDR-TB Patients. 
In this study, family assistance was not re-
lated to the success of treatment (OR= 1.85; 
95% CI= 0.19 to 17.43; p= 0.590). Based on 
the results of direct interviews conducted 
by the studyers to patients, it showed that 
the success of patients' treatment was due 
to the big desire to recover or personal 
motivation of the patient so that the pre-
sence of family assistance did not affect the 
success of treatment.  
This was not in accordance with the 
results of previous studies which stated that 
MDR TB patients need social support to 
improve their quality of life. Good relation-
ships in the family affected the success of 
treatment (Morris et al., 2013).   
8. The Relationship between Drug 
Side Effects and Successful Treat-
ment of MDR-TB Patients 
Drug side effects were significantly as-
sociated with successful treatment of MDR 
TB patients, with the score of p = 0.001 in 
severe side effects and moderate side effects 
(OR= 0.04; 95%CI= 0.01 to 0.24; p<0.001).  
This was in accordance with a study 
done by Deshmuckh et al. (2015), which 
stated that there were many factors which 
affect the adherence to treatment of MDR-
TB patients, including the presence of drug 
side effects experienced by MDR-TB pa-
tients. Another study also mentioned that 
drug side effects affected the quality of life 
of MDR-TB patients (Zai et al., 2010). 
9. The Relationship between Family 
Support and Successful Treatment 
of MDR-TB Patients 
Family supports, including emotional 
support (OR= 0.89; 95% CI=0.567 to 1.42; 
p= 0.65), appreciation support (OR= 1.04; 
95% CI= 0.54 to 2.03; p= 0.90), infor-
mation support (OR= 1.16; 95% CI= 0.75 to 
1.78; p= 0.49), and instrumental support 
(OR= 1.01; 95% CI= 0.69 to 1.45; p= 0.985) 
were not related to the success of MDR-TB 
treatment. This was not in accordance with 
a study done by Tupasi et al., (2016) which 
stated that there was a relationship between 
family support and the possibility of drop 
out in MDR-TB patients (OR= 0.92; 95% 
CI= 0.85 to 1.00; p= 0.047). Similar to a 
study conducted by Deshmuckh et al., 
(2015) which stated that one of the factors 
that affect the success of MDR-TB treat-
ment was family support. 
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10. The Relationship between Nutri-
tional Status and Successful 
Treatment of MDR-TB Patients. 
Nutritional status of MDR-TB patients was 
not related to the success of treatment 
(OR= 2.07; 95% CI= 0.47 to 3.02; p= 
0.718). This was in accordance with a study 
done by Tupasi et al., (2016) which stated 
that there was no relationship between 
nutritional status (Body Mass Index) and 
the possibility of drop out in MDR-TB 
patients (OR=1.17; 95% CI= 0.7 to 1.94; 
p=0.55). 
The success of treatment in   Tuber-
culosis Multi Drug Resistant (MDR-TB) 
patients was affected by age and drug side 
effects, especially severe and moderate, 
while minor /normal side effects have no 
effect on the success of treatment. Likewise 
with other independent variables that did 
not show a relationship with the success of 
treatment, which were gender, education, 
distance to health facilities, employment, 
marital status, family assistance, family 
support, and nutritional status. 
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